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November is lung cancer awareness month in most countries of our readership. Unfortunately, this month slips by with most people including health care workers, not 
even realizing that the month has been set aside to recognize and affirm the fight against this 
deadly disease. The lack of recognition is made more striking by the fact that November fol-
lows October—breast cancer awareness month, which is widely celebrated globally. Thus, 
November is a good month for Journal of Thoracic Oncology to reflect on the accomplish-
ments in research, screening, prevention, and treatment of this disease.
The most accurate global data on lung cancer are about 5 years old. These data indi-
cate that lung cancer is the most common cancer in the world, with an estimated 1.61 mil-
lion new cases a year, representing 12.7% of all new cancers. It is also the most common 
cause of cancer death, accounting for 18% of the total or 1.38 million deaths.1 To put these 
numbers in perspective, the equivalent mortality statistic from acquired immuno-deficiency 
syndrome, arguably the most devastating human epidemic in recent memory was 2 million 
deaths. Given these data, why are all nations, governmental and nongovernmental agencies 
not spending significant resources and efforts in preventing this disease?
Lung cancer is one of the few cancers for which the major cause has been identified. 
The causative link between tobacco use and lung cancer was established over 60 years ago.2 
Approximately 90% of lung cancers occur in smokers or those with a history of smoking. 
Global lung cancer incidence rates closely mirror smoking prevalence.1 Since the introduc-
tion of manufactured cigarettes just over 125 years ago, global tobacco use has risen steadily. 
Currently, it is estimated that there are more than one billion smokers worldwide, roughly 
a quarter of the world adult population.3 Tobacco control programs are being established in 
the major industrialized countries. However, in many developing countries, the consumption 
of cigarettes is increasing rapidly in both sexes, attributable to population growth and the 
increased targeting of tobacco marketing in these areas, particularly to the youth.
The most successful approach to combating deadly diseases has been prevention, 
screening, and early detection. Although the supporting data are still debated, screening is 
currently established in three common cancers, breast, colorectal, and prostate cancer. For 
the first time in the United States, a large, randomized controlled trial, the National Lung 
Screening Trial (NLST) screened over 50,000 adults at high risk for lung cancer (current or 
former smokers aged 55 to 74 years with a ≥30 pack-year history of cigarette smoking and 
≤15 years since quitting), with low-dose computed tomography scans (LDCT) or single-
view posterior anterior chest radiography. This study demonstrated a relative reduction of 
death from lung cancer with low-dose screening of 6.7% and a reduction in all-cause mor-
tality of 20% in the LDCT group compared with the chest radiography group.4
On the basis of this study, a number of academic societies have recommended screening 
for lung cancer with LDCT. The American College of Chest Physicians, the American Society 
of Clinical Oncology, the American Thoracic Society, the American Association for Thoracic 
Surgery, the American Cancer Society, and the National Comprehensive Cancer Network have 
recommended screening with eligibility criteria similar to that of NLST. The International 
Association for the Study of Lung Cancer (IASLC) Task Force on computed tomography (CT) 
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screening reviewed NLST results and concluded that it is appro-
priate for heavy smokers who were 55 to 74 years of age to discuss 
relevant lung cancer screening information with their physicians 
to assist them in deciding whether to undergo spiral CT screening. 
A few months ago, the U.S. Preventive Services Task Force issued 
draft guidelines recommending annual screening for lung cancer 
with LDCT in persons at high risk for lung cancer based on age 
and smoking history.5 It is noteworthy that all the guidelines in 
lung cancer screening are based in North America. There are issues 
with cost, accurate interpretation of LDCT, as well as minimally 
invasive techniques of interventions for screen-detected lesions, 
which are not available in low- and middle-income countries, and 
this can significantly alter the risk to benefit ratio of LDCT in 
these countries. Results of other global screening studies such as 
the Nederlands-Leuvens Longkanker Screenings Onderzoek trial6 
which will provide additional information on cost effectiveness 
and clinical management outcomes of lung cancer screening will 
be helpful in coming up with more global guidelines.
In the systemic therapy of advanced disease, after several 
negative phase 3 trials of novel agents in lung cancer over the last 
decade (such as sorafenib, figitumumab, lonafarnib, ASA404, 
PF-3512676, ISIS-3521, prinomastat, bexarotene, talactoferrin 
alpha, tivantinib), developments in genomics have uncovered 
driver molecular aberrations that predict for dramatic responses 
to targeted therapies. Actionable aberrations with clinical data on 
efficacy of target-directed therapies include epidermal growth 
factor receptor (EGFR), BRAF, and human epidermal growth 
factor receptor 2 (HER2) mutations, as well as echinoderm 
microtubule-associated protein-like 4 gene fused to the anaplas-
tic lymphoma kinase gene (EML4-ALK), ROS1, and rearranged 
during transfection (RET) translocations. Aberrations with 
no robust efficacy data for targeting drugs include phosphati-
dylinositol-4,5-bisphophate 3-kinase, catalytic subunit alpha 
(PIK3CA), AKT, and discoidin domain receptor tyrosine kinase 
2 (DDR2) mutations, as well as FGFR amplification. Recently 
described potentially targetable aberrations include FGFR and 
neurotrophic tyrosine kinase, receptor, type 1 (NTRK1) fusions.7 
However, tumor heterogeneity and plasticity is a particularly 
complicated issue, leading to resistance of genetically driven 
tumors and precluding cures and long-term survival. Attention 
needs to be paid to classical pharmacology, particularly pharma-
cokinetics-pharmacodynamics relationships, and careful phase I 
combination studies need to be performed to successfully com-
bine these novel agents, because combination therapy has been 
the only successful approach in treating/curing complex human 
disease, from tuberculosis through acquired immuno-deficiency 
syndrome to testicular cancer. Thus, lung cancer has evolved 
from a tumor treated empirically with toxic, ineffective drugs to 
a tumor at the forefront of genomic medicine.
In spite of these successes, a lot is left to be done. Most 
of the current progress is in non–small-cell lung cancer. Novel 
agents and innovative approaches are almost non-existent in 
small cell lung cancer. Currently all 20,000 protein-coding 
human genes have been evaluated in the genome-wide sequenc-
ing studies of 3284 tumors from different organs. Of the total 
of 2,94,881 mutations reported, only 138 driver mutations, of 
which 74 are tumor-suppressor genes and 64 are oncogenes, 
have been identified to date.8Thus, even for non–small-cell lung 
cancer, which contains numerous mutations, with on average 
about 200 mutations identified in a single tumor, the number 
of actionable genetic alterations are finite, and likely to be fully 
catalogued in the next couple of years. Thus, undoubtedly, there 
will be a significant number of wild-type lung cancers that will 
also need to be treated. Novel, non–genomic-based agents such 
as immunomodulatory anti–programmed cell death-1 and pro-
grammed cell death ligand-1 antibodies, heat shock protein 90 
inhibitors, and antiapoptotic agents will therefore be important 
tools in the antilung cancer armamentarium.
Next, and of particular relevance to the IASLC, global 
variations in health care systems and national wealth is a chal-
lenge that has to be addressed to continue the gains in lung can-
cer. Cigarette smoking is declining in the industrialized Western 
countries, although there is no such decline in large parts of 
Asia, Eastern and Central Europe, and South America. Tobacco 
control should be global and the World Health Organization’s 
MPOWER program needs to be adopted by all countries.9 This 
journal will play a role in highlighting the basic and transla-
tional science as well as public policy and epidemiologic 
research issues in tobacco carcinogenesis and tobacco control.
Finally, the cost and availability of novel medications for 
treating lung cancer is a significant barrier. Thus, despite the 
exciting data with EML4-ALK inhibitors, EML4-ALK rear-
rangement testing and crizotinib are available to only a small 
minority of lung cancer patients worldwide. The situation 
will be no different for low-incidence molecular alterations 
in other genes such as ROS1, RET, FGFR, and DDR2, which 
are identified through sequencing, flourescent in situ hybrid-
ization, or other complex molecular techniques. Simpler and 
low-cost analytic assays need to be developed, and the cost of 
anticancer agents will need to be lowered. Otherwise, cura-
tive combination therapies will be financially toxic even to the 
affluent nations of the world. The future for lung cancer diag-
nosis, prevention, and treatment is bright, and the IASLC and 
this journal will be at the forefront, leading the charge.
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